A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

Clinical trial NCT06236880 · RECRUITING

Trial details

NCT number: NCT06236880
Sponsor: Gilgamesh Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Major Depressive Disorder

Start date: 2024-01-31
Primary completion: 2026-10-01
Enrollment: 124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.